Splice-switching ASOs targeting the AURKA 5′ UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer
Molecular Cell · 2026-01 · 86 (1) · 60-77.e7
DOI: 10.1016/j.molcel.2025.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2026-01. Verfasst von Alexander J Kral und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Department of Microbiology & Immunology, Renaissance School of Medicine, Stony Brook Univ…. Hauptthemen laut MEDLINE: Aurora Kinase A, Serine-Arginine Splicing Factors, 5' Untranslated Regions, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, Cold Spring Harbor Laboratory.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, driven by oncogenic KRAS mutations and dysregulated oncogenes, including SRSF1, MYC, and Aurora kinase A (AURKA). Although KRAS-targeted therapies are in development, resistance mechanisms underscore the need to identify alternative vulnerabilities. Here, we uncover an SRSF1-AURKA-MYC oncogenic circuit, wherein SRSF1 regulates AURKA 5' UTR alternative splicing, enhancing AURKA protein expression; AURKA positively regulates SRSF1 and MYC post-translationally, independently of its kinase activity; and MYC transcriptionally upregulates both SRSF1 and AURKA. Elevated SRSF1 in tumor cells promotes inclusion of an Alu-derived exon in the AURKA 5' UTR, resulting in splicing-dependent mRNA accumulation and exon-junction-complex deposition. Modulating 5' UTR splicing with splice-switching antisense oligonucleotides (ASOs) collapses the oncogenic circuit, reducing PDAC cell viability and triggering apoptosis. Our findings identify AURKA alternative splicing as a critical regulatory node and highlight a potential therapeutic strategy that simultaneously targets SRSF1, AURKA, and MYC oncogenes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Department of Microbiology & Immunology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Graduate Program in Molecular & Cellular Biology, Stony Brook University, Stony Brook, NY, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. Electronic address: krainer@cshl.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- Cold Spring Harbor Laboratory
Zitieren
APA
Kral, A. J., Jia, L., Sim, G., Wan, L., Ishigami, Y., & Krainer, A. R. (2026). Splice-switching ASOs targeting the AURKA 5′ UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Molecular Cell, 86(1), 60-77.e7. https://doi.org/10.1016/j.molcel.2025.12.004
Vancouver
Kral AJ, Jia L, Sim G, Wan L, Ishigami Y, Krainer AR. Splice-switching ASOs targeting the AURKA 5′ UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Molecular Cell. 2026;86(1):60-77.e7. doi:10.1016/j.molcel.2025.12.004
BibTeX
@article{Kral2026,
author = {Kral, Alexander J and Jia, Lu and Sim, GeunYoung and Wan, Ledong and Ishigami, Yuma and Krainer, Adrian R},
title = {Splice-switching ASOs targeting the AURKA 5′ UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer},
journal = {Molecular Cell},
year = {2026},
volume = {86},
number = {1},
pages = {60--77.e7},
doi = {10.1016/j.molcel.2025.12.004}
}
EUVIMED